Observational studyCurrent oncology (Toronto, Ont.)2023
Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors.
Observational study in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Comparative efficacy of different exercise interventions for cancer-related fatigue, health-related quality of life, anxiety and depression symptoms in cancer survivors: a systematic review and network meta-analysis.BMC public health · 2026Pooled it
- Trial
- Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial.BMC geriatrics · 2025Trial
- Effect of Structured Exercise-based rehabilitation on Sarcopenia and Quality of life among Head and Neck Cancer Patients Undergoing Chemo-radiotherapy: A Randomized Controlled Trial.Asian Pacific journal of cancer prevention : APJCP · 2025Trial
- A bacteria-releasing mucoadhesive sheet for localized delivery and penetrative therapy of gastrointestinal cancer.Materials today. Bio · 2026Article
- Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Role of Family Medicine in Integrative Prevention and Management of Oncologic Diseases in Romania.Healthcare (Basel, Switzerland) · 2026Review
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- The Interplay of Quality of Life and Satisfaction with Nursing Care in Cancer Patients: A Narrative Review.Clinics and practice · 2026Review
- Impact of Hypertrophy-Oriented Resistance Training on Muscle Mass and Quality of Life in Patients with Unresectable Pancreatic Cancer (HY-PANC): Study Protocol for a Randomized Controlled Trial.Current protocols · 2026Article
- Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line Chemo-Immunotherapy.Clinical and translational radiation oncology · 2026Article
- Review
- Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy.Biomolecules · 2026Article
- Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study.Breast cancer research and treatment · 2026Article
- Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity.Frontiers in cell and developmental biology · 2026Review
- Research Advances on Targets and Mechanisms in Cancers Complicated by Cardiovascular Diseases.OncoTargets and therapy · 2026Review
- 18β-glycyrrhetinic acid inhibits lung adenocarcinoma progression by targeting the MET/AKT signaling axis.Frontiers in cell and developmental biology · 2026Article
- Pharmacogenomic variation and chemotherapy-related toxicity profiles in pediatric patients with cancer in Tanzania: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Review
- Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of the study was to identify subgroups of advanced cancer patients who experienced grade 3-4 toxicities as reported by their oncologists as well as identify the demographic, clinical, and treatment symptom characteristics as well as QoL outcomes associated with distinct profiles of each patient. A prospective, multicenter, observational study was conducted with advanced cancer patients of 15 different hospitals across Spain. After three months of systemic cancer treatment, participants completed questionnaires that evaluated psychological distress (BSI-18), quality of life (EORTC QLQ-C30) and fatigue (FAS). The most common tumor sites for the 557 cancer patients with a mean age of 65 years were bronchopulmonary, digestive, and pancreas. Overall, 19% of patients experienced high-grade toxicities (grade 3-4) during treatment. Patients with recurrent advanced cancer, with non-adenocarcinoma cancer, undergoing chemotherapy, and a showing deteriorated baseline status (ECOG > 1) were more likely to experience higher toxicity. Patients who experienced grade 3-4 toxicities during cancer treatment had their treatment suspended in 59% of the cases. Additionally, 87% of the patients had a dose adjustment or a cycle delayed in their treatment due to a high risk of dying during treatment. Future research should focus on identifying interventions to reduce high-grade toxicities and improve quality of life in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.